Not yet recruitingPriority 3 · Moderate priorityNCT07139353
Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
Plain-language summary
This trial is testing chidamide (an oral HDAC inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Linperlisib (DRUG): Linperlisib: 80 mg or 60 mg, po, qd (phase Ib); RP2D (phase II) | Chidamide (DRUG): Chidamide: 20mg, po, biw
Linperlisib, Chidamide
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details